Tempest Therapeutics, Inc.
TPST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.06 | 0.01 | 0.00 |
| FCF Yield | -11.05% | -40.58% | -238.29% | -1,698.17% |
| EV / EBITDA | -7.17 | -1.71 | -0.13 | 1.23 |
| Quality | ||||
| ROIC | -121.85% | -61.48% | -86.12% | -49.38% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.79 | 0.93 | 0.87 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -21.56% | 12.98% | -21.24% | -36.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.37 | 0.65 | 0.28 | 1.29 |
| Interest Coverage | -31.93 | -20.12 | -21.41 | -21.05 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,298.84 | -809.51 | 0.00 | 0.00 |